# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0000886163-17-000114
Filing Date
2017-10-04
Accepted
2017-10-04 16:47:39
Documents
8
Period of Report
2017-10-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | a8k-crystalmerger8k.htm | 8-K | 57427
2 | EXHIBIT 2.1 | exhibit21-crystalmergeragr.htm | EX-2.1 | 769213
3 | EXHIBIT 99.1 | ligandtoacquirecrystalbi.htm | EX-99.1 | 17262
4 |  | ligandtoacquirecrystalbi001.jpg | GRAPHIC | 182689
5 |  | ligandtoacquirecrystalbi002.jpg | GRAPHIC | 192580
6 |  | ligandtoacquirecrystalbi003.jpg | GRAPHIC | 215030
7 |  | ligandtoacquirecrystalbi004.jpg | GRAPHIC | 273866
8 |  | ligandtoacquirecrystalbi005.jpg | GRAPHIC | 4086
| Complete submission text file | 0000886163-17-000114.txt |  | 2037624

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 171122199
SIC: 2834 Pharmaceutical Preparations